Last Posted: Feb 15, 2019
- Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions.
Pan R-Y et al. Clinical pharmacology and therapeutics 2017 102(1) 86-97
- Stevens-Johnson syndrome/toxic epidermal necrolysis in Jewish and Arab populations.
Firer Maria et al. Epilepsia 2018 59(7) 1469-1470
- Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.
Yu Kuang-Hui et al. International journal of rheumatic diseases 2017 Sep 20(9) 1057-1071
- Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee.
Vassy Jason L et al. Genetics in medicine : official journal of the American College of Medical Genetics 2018 Jun
- Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population.
Mushiroda Taisei et al. JAMA neurology 2018 Apr
- The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.
Jutkowitz Eric et al. Seminars in arthritis and rheumatism 2017 Apr 46(5) 594-600
- Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.
Chong Huey Yi et al. Pharmacogenetics and genomics 2017 Nov
- Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis.
Manolio Teri A et al. Clinical pharmacology and therapeutics 2017 Nov
- A success story in pharmacogenomics: genetic ID card for SJS/TEN.
Sukasem Chonlaphat et al. Pharmacogenomics 2016 Apr 17(5) 455-8
- Personalized medicine approaches in epilepsy.
Walker L E et al. J. Intern. Med. 2015 Feb (2) 218-34
- Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.
- Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population.
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Quick Links to Other Resources
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Jul 30, 2019
- Page last updated:Aug 24, 2019
- Content source: